Lazard Asset Management LLC Increases Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Lazard Asset Management LLC lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,777 shares of the company’s stock after buying an additional 338 shares during the quarter. Lazard Asset Management LLC’s holdings in IDEXX Laboratories were worth $3,214,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. Hurley Capital LLC purchased a new stake in IDEXX Laboratories during the 4th quarter worth approximately $29,000. Rialto Wealth Management LLC purchased a new stake in IDEXX Laboratories during the 4th quarter worth approximately $30,000. Retirement Wealth Solutions LLC purchased a new stake in IDEXX Laboratories during the 4th quarter worth approximately $31,000. Colonial Trust Co SC increased its holdings in IDEXX Laboratories by 84.8% during the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company’s stock worth $35,000 after purchasing an additional 39 shares during the last quarter. Finally, Kestra Investment Management LLC purchased a new stake in IDEXX Laboratories during the 4th quarter worth approximately $38,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on IDXX. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Friday, May 9th. Piper Sandler lifted their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. Stifel Nicolaus decreased their target price on IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating for the company in a research report on Monday, April 14th. Barclays lifted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Finally, Bank of America lifted their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus price target of $524.75.

IDEXX Laboratories Trading Up 1.2%

NASDAQ:IDXX opened at $518.10 on Friday. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $545.43. The firm has a market capitalization of $41.67 billion, a P/E ratio of 48.56, a P/E/G ratio of 3.41 and a beta of 1.52. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The business has a 50 day simple moving average of $431.28 and a 200 day simple moving average of $431.42.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The business had revenue of $998.43 million during the quarter, compared to analyst estimates of $998.25 million. During the same quarter in the previous year, the firm posted $2.71 EPS. The business’s revenue for the quarter was up 3.6% compared to the same quarter last year. Equities research analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.